Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9252W HIGH $28.13
Volume
75.15 K
Value Traded
102.29 K
Short % Float
1.88%
-8.91%Week
+8.86%1 Month
+68.63%3 Month
+103.95%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
19.68 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
3.81 M
Float Shares
2.56 M
Insiders
32.93%
Institutions
9.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PBM Catalyst Timeline
Dated clinical, regulatory and corporate events for Psyence Biomedical Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Psyence Biomedical Ltd.
170Total events
4Upcoming
38Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseibogaineCorporate
Psyence BioMed's TIRC enters binding term sheet with PsyLabs for exclusive U.S. ibogaine license
▲Partnership / LicenseCorporate
Psyence BioMed and PsyLabs agree to value-matched share exchange (~US$9 million each side)
●Equity OfferingCorporate
Psyence BioMed irrevocably commits US$2.4M to subscribe for 936 PsyLabs ordinary shares at US$2,564/share
●Timing GuidancePresentation
Texas Ibogaine Research Corporation (TIRC) established as dedicated U.S. subsidiary for planned ibogaine development
●Management ChangeCorporate
Texas Ibogaine Research Corporation (TIRC) established as dedicated U.S. subsidiary
●Management ChangeCorporate
Dr. John Thorne appointed project lead of Texas Ibogaine Research Corporation
●Timing GuidancePresentation
Formation of Texas Ibogaine Research Corporation (TIRC) as U.S. ibogaine development vehicle
▲Other Regulator MilestoneEx-US Regulatory
President Trump announces University of Miami provided original 1994 ibogaine IND to U.S. Federal Government
▲Other Regulator MilestoneibogaineEx-US Regulatory
Coordinated federal implementation announced for neuroplastogen research
▲Timing GuidancePresentation
Coordinated federal implementation of neuroplastogen research policy announced
▲First Patient DosedNPX-5Trial
First patient dosed in Phase IIb trial of NPX-5 for Adjustment Disorder
Adjustment Disorder in patients with cancer in a palliative care settingsource ↗
▲Other Regulator MilestoneibogaineEx-US Regulatory
Executive Order signed directing federal agencies to accelerate neuroplastogen research
▲Timing GuidancePresentation
Executive Order directing federal agencies to accelerate neuroplastogen research
▲Enrollment UpdateNPX-5Trial
Expansion of clinical site network from three to five sites in Australia
Adjustment Disorder in patients with cancer in a palliative care settingsource ↗
▲Manufacturing MilestoneNPX-5CMC / Inspection
Export of GMP-manufactured NPX-5 capsules to Australia
◆Quarterly UpdateCorporate
Annual and Special Meeting of Shareholders to consider financial statements, auditor appointment, director election, and share consolidation
◆Reverse Stock SplitCorporate
Postponement of previously announced 1-for-6.25 reverse stock split effective date
▲Manufacturing MilestoneCMC / Inspection
First Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride
▲Trial InitiationpsilocybinTrial
Phase 2b psilocybin clinical trial underway
mental health disorderssource ↗
●Preclinical PoCpsilocybinPreclinical
Full acceleration of preclinical protocol expected after ethics approval
longevitysource ↗
▲IND ClearanceNPX-5IND
Bellberry HREC approval for use of PsyLabs' psilocybin product (NPX5) in Phase IIb trial
Adjustment Disorder in patients with cancersource ↗
▲First Patient DosedNPX-5Trial
First patients dosed with NPX-5 in Phase IIb trial in Australia
Adjustment Disorder in patients with cancer in a palliative care contextsource ↗
●Management ChangeCorporate
Christopher Bull resigned as director; Graham Patrick appointed to Board
◆Topline Readoutnature derived psilocybinClinical Data
Topline data from Phase IIb study expected end of 2025
Adjustment Disorder in Palliative Caresource ↗
●Preclinical PoCpsilocybinPreclinical
Launch of psilocybin longevity research program
longevitysource ↗
▲Manufacturing MilestoneibogaineCMC / Inspection
Established sustainable supply of high-potency iboga bark; first 50 kg received and being processed into ibogaine HCL
substance use disorderssource ↗
▲Partnership / LicenseCorporate
Strategic investment in PsyLabs establishing ibogaine operations in Africa
▲First Patient Dosednature derived psilocybinTrial
Multiple patients dosed in Phase IIb study for Adjustment Disorder in palliative care
Adjustment Disorder in palliative caresource ↗
▲Enrollment Updatenature derived psilocybinTrial
Expanded to three actively enrolling sites
Adjustment Disorder in palliative caresource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseCorporate
Psyence BioMed makes USD $3,500,000 follow-on investment in PsyLabs
◆Trial InitiationTrial
Steering Committee established for early-phase psilocybin study in AUD
Alcohol Use Disordersource ↗
◆Timing GuidancePresentation
Webinar with Scientific Advisory Board to be hosted in coming weeks
▲Manufacturing MilestoneCMC / Inspection
PsyLabs produces GMP-aligned Ibogaine Total Alkaloid extract meeting microbial safety standards
▲Manufacturing MilestoneCMC / Inspection
PsyLabs produced GMP-aligned Ibogaine Total Alkaloid extract
◆Oral PresentationPresentation
Chief of Global Impact to speak at Psychedelic Science 2025 Business Track panel 'We are the Guardrails: Profit with Purpose'
◆Trial InitiationPEX010Trial
Appointment of CRO to rescue and conduct Ph IIb trial of PEX010
Adjustment Disorder in terminal cancer patientssource ↗
▼Reverse Stock SplitCorporate
Nasdaq delisting determination due to bid price deficiency; company may consider reverse stock split to regain compliance
▲Partnership / LicenseCorporate
Psyence BioMed makes USD $500,000 initial investment in PsyLabs
Past FDA Catalysts and PDUFA Decisions
How PBM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$6M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Top 93%
Micro Cap(rank 612 of 658)
Percentile Rank
Psyence Biomedical Ltd. faces pipeline headwinds (21/100), with $368M risk-adjusted pipeline value, led by Psilocybin therapy in Adjustment Disorder (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psilocybin therapy Small moleculeNCT07072728 | Adjustment Disorder | Phase 2 | RECRUITING | 87 | Jul 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PBM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PBM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PBM for Q2 2026. | ||||
PBM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PBM ranks across every disease it competes in
Competitive Position is a premium feature
See how PBM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPBM News
PBMPsyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation, has secured an exclusive U.S. license for pharmaceutical-grade ibogaine from PsyLabs. This agreement provides TIRC with rights to develop and distribute ibogaine, contingent on a definitive agreement by November 30, 2026. The collaboration aims to expedite the development of ibogaine drug candidates to meet mental health needs.
Read more →PBMPsyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has announced a strategic investment of up to $5 million in PsyLabs, along with a value-matched share exchange valued at approximately $9 million. This initiative aims to support the development of pharmaceutical-grade ibogaine for a potential clinical trial targeting Opioid Use Disorder in Texas. The establishment of the Texas Ibogaine Research Corporation will facilitate regulatory and clinical activities for the U.S. program.
Read more →PBM▲ +11.1%on this news
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Psyence BioMed has established the Texas Ibogaine Research Corporation to coordinate U.S. development of pharmaceutical-grade ibogaine. This entity aims to streamline supply, regulatory engagement, and clinical development efforts. The formation follows recent U.S. policy developments promoting ibogaine research, with plans for future licensing and regulatory activities. Jody Aufrichtig will lead TIRC as CEO.
Read more →PBM▼ -8.3%on this news
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed has welcomed the U.S. government's announcement to accelerate ibogaine development, aligning with their pharmaceutical platform. President Trump highlighted the submission of the original ibogaine IND application by the University of Miami, which could expedite clinical research. The company is actively engaging with stakeholders to advance ibogaine's clinical development.
Read more →PBMPsyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
Psyence Group Inc. announced the results of its annual general and special meeting where shareholders approved all proposed matters, including a significant amalgamation transaction with GoldCoast Resource Corp. The meeting confirmed the current board's election and proposed new directors for the resulting entity. However, the completion of the transaction is contingent upon regulatory approvals.
Read more →PBMPsyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Ltd. announced a strategic engagement initiative in the U.S. to promote GMP ibogaine research and manufacturing. The company's leadership will meet with key stakeholders to discuss regulatory considerations and scientific infrastructure. This initiative follows recent U.S. policy changes supporting psychedelic research, and Psyence aims to educate on compliant ibogaine production.
Read more →PBM▼ -12.4%on this news· ran to -44% by day 3
Psyence Group Inc. Announces Amendment to Amalgamation Agreement with GoldCoast Resource Corp.
Psyence Group Inc. has announced an amendment to its amalgamation agreement with GoldCoast Resource Corp. The amendment adjusts the share consolidation formula to reflect current conditions. The transaction's completion is contingent upon shareholder and regulatory approvals, with an annual meeting scheduled for May 19, 2026, to discuss the transaction.
Read more →PBMPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence Biomedical Ltd. has commenced patient dosing in its Phase IIb clinical trial assessing NPX-5, a psilocybin treatment for Adjustment Disorder in cancer patients receiving palliative care. This trial marks the first significant human evaluation of NPX-5 and aims to evaluate its safety and efficacy across multiple sites in Australia. The company seeks to generate critical clinical data to inform future development and regulatory pathways while addressing a significant psychological need in this patient population.
Read more →PBM▲ +48.7%on this newsshared move
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence Biomedical Ltd. has established itself as the only licensed supplier of pharmaceutical-grade ibogaine by developing a vertically integrated platform for sourcing, manufacturing, and supplying ibogaine. The company has positioned itself to support the scientific and clinical research community as regulatory interest in ibogaine grows. By securing direct access to the natural source of ibogaine in Africa and maintaining a GMP-compliant inventory, Psyence aims to address the existing supply gaps in the market. Their capabilities will enable continued research and potential commercialization of ibogaine-based therapies.
Read more →PBM▲ +29.5%on this news· ran to +93% by day 1shared move
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed has welcomed reports of an upcoming U.S. executive order aimed at evaluating the safety and therapeutic potential of ibogaine, a compound thought to aid in treating PTSD and addiction. The move is seen as a necessary step toward regulated research in areas with limited treatment options. The company emphasizes the importance of controlled clinical research and has also established a GMP-compliant manufacturing presence for ibogaine. With increased interest in ibogaine, Psyence aims to support scientific progress through ethical sourcing and a robust supply chain.
Read more →PBMPsyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence Biomedical Ltd. announced the expansion of its Australian clinical site network from three to five sites, including the addition of Ramsay Health Care and NeuroCentrix. This expansion is aimed at strengthening recruitment and accelerating enrollment for its ongoing Phase IIb clinical trial evaluating natural psilocybin for treating Adjustment Disorder in cancer patients. The company's move is expected to broaden its operational efficiency and support patient dosing. CEO Jody Aufrichtig emphasized the importance of this growth for generating meaningful clinical data.
Read more →PBM▲ +8.2%on this news
Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering
Psyence Group has announced that GoldCoast Resource Corp. has successfully completed the second tranche of its financing, raising $2,778,119. This is part of a larger offering totaling $8,603,883, aimed at funding exploration activities. The completion of this offering is a key condition for the proposed amalgamation between Psyence and GoldCoast, which remains subject to regulatory approvals.
Read more →PBMPsyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.
Psyence Group Inc. has announced an update regarding its proposed amalgamation with GoldCoast Resource Corp. GoldCoast has completed a brokered private placement, raising over $5.8 million to fund exploration activities. However, the completion of the amalgamation remains contingent on various approvals and conditions, with no guarantee of finalization.
Read more →PBMCorporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed has advanced its vertically integrated pharmaceutical platform through a strategic investment in PsyLabs, enhancing its manufacturing and supply chain capabilities. The company has achieved a key milestone by exporting its first clinical trial product to Australia. Psyence BioMed emphasizes disciplined capital allocation and aims for sustainable growth while navigating the evolving psychedelic therapeutics market.
Read more →PBMPsyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed has successfully exported its GMP-manufactured psilocybin product NPX-5 to Australia for a Phase IIb clinical trial. This trial aims to evaluate the efficacy of natural psilocybin in treating Adjustment Disorder in cancer patients. The company emphasizes its commitment to quality and regulatory compliance while pioneering the use of nature-derived psychedelics in mental health care.
Read more →PBMPsyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.
Psyence Group Inc. has entered an amending agreement with GoldCoast Resource Corp. to extend the timeline for their proposed amalgamation. Key changes include extending the shareholder meeting deadline and reducing the minimum cash condition for closing. However, trading in Psyence's shares is halted, and completion of the transaction is uncertain.
Read more →PBMPsyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs exercised its put option, enabling a strategic equity investment where Psyence will acquire shares in PsyLabs. This exercise aims to strengthen the collaboration between the two companies, enhancing Psyence's access to high-quality psychedelic manufacturing resources. The transaction involves a Share-for-Share Exchange, resulting in PsyLabs obtaining roughly 49.98% ownership of Psyence's common shares. While this aligns with Psyence's long-term growth objectives, it poses risks of dilution for existing shareholders and significant influence over governance.
Read more →PBM▼ -9.7%on this newsshared move
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence Biomedical Ltd. announced the results of its Annual and Special Meeting of Shareholders held on February 12, 2026. Shareholders approved all proposed business matters, including the election of directors and the appointment of auditors. Additionally, they authorized the board to consolidate shares at a ratio of up to 250:1, pending regulatory approvals.
Read more →PBM▲ +10%on this newsshared move
Psyence BioMed Approves a Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway The Put Option Agreement positions Psyence BioMed for potential significant future equity pa
Psyence BioMed has ratified a Put Option Agreement with PsyLabs, which allows PsyLabs to require Psyence to make an equity investment in exchange for access to its manufacturing capabilities. This agreement is designed to secure a reliable supply of pharmaceutical-grade psychedelics as Psyence advances its commercialization strategy. The partnership positions Psyence to mitigate risks related to regulatory and supply-chain challenges, enabling more secure planning for future clinical programs. The arrangement also preserves the company's financial flexibility while aiming to strengthen their product pipeline.
Read more →About Psyence Biomedical Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next PBM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime